Yearly Archives: 2016

ARMO BioSciences, Inc., a clinical-stage immuno-oncology company, announced that the European Commission (EC) has granted the Company’s lead investigational immuno-oncology drug AM0010 (PEGylated Interleukin-10) Orphan designation for the treatment of pancreatic cancer. The EC’s approval follows a positive opinion in November … Continued

Muse bio today announced the publication of a paper in Nature Biotechnology describing, for the first time, its foundational technology platform that enables rational engineering of the whole genome with single-nucleotide precision. The technology, “CRISPR-enabled trackable genome engineering” (CREATE), has … Continued

Muse bio, a privately-held company leading the development of next-generation genome engineering technologies, today announced that Dr. Kevin Ness has been appointed Chief Executive Officer and member of the Board of Directors. Kevin succeeds Muse bio’s founding CEO Ryan Gill, … Continued

SQZ Biotech announced today an additional $8 million in Series B financing from GV (formerly known as Google Ventures) and Quark Venture Inc. The funding augments an earlier closing of $16 million led by NanoDimension and Polaris Partners in September … Continued

ARMO BioSciences, Inc., a clinical-stage biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has granted the Company’s lead investigational immuno-oncology drug AM0010 (PEGylated Interleukin-10) Orphan Drug designation for the treatment of pancreatic cancer. The Agency also granted … Continued

Emulate Inc. announced today that its human Lung-Chip system has expanded functionality to now also model conditions in which inhaled toxins enter the lung, including cigarette smoke, e-cigarettes constituents, and potentially environmental airborne contaminants. The new applications are based on … Continued

Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biopharmaceutical company developing a novel class of targeted antigen-specific immune therapies, today announced that it has dosed the first patient in its Phase 2 clinical trial of SEL-212, the company’s lead proprietary immunotherapeutic product … Continued

Emulate, Inc. announced today its strategic collaboration with the Lawrence J. Ellison Institute for Transformative Medicine of USC to use Emulate’s Organs-on-Chips technology to conduct leading-edge translational R&D that can advance cancer treatment and patient well-being. Emulate and the Ellison … Continued

There is an ecosystem of many stakeholders who play a role in the discovery of new drugs, and each of them have a vested interest in making the drug discovery system work successfully and efficiently. Yet, the realities of a … Continued